New and Emerging Targeted Therapies for Advanced Breast Cancer.
New and Emerging Targeted Therapies for Advanced Breast Cancer.
复制标题
DOI：
10.3390/ijms23042288
复制
发表时间：
2022-02-18
影响因子：
5.6
通讯作者：
Shi Y
中科院分区：
文献类型：
--
作者：
Lau KH;Tan AM;Shi Y
在美国，乳腺癌是女性中最常见的癌症之一。根据组织病理学标准，包括激素受体（雌激素受体和/或孕酮受体）和/或HER 2的表达，乳腺癌分为四种主要亚型：人表皮生长因子受体2（HER 2）、Luminal-A、Luminal-B和基底样或三阴性。原发性乳腺癌治疗可包括手术、放射疗法、全身化疗、内分泌疗法和/或靶向疗法。内分泌治疗已被证明是有效的激素受体阳性乳腺癌，是一种常见的选择辅助治疗。然而，由于三阴性乳腺癌的侵袭性，靶向治疗正在成为寻找乳腺癌非内分泌靶点的一个值得注意的研究领域。除了HER 2靶向治疗外，其他新兴疗法包括针对细胞生长中的关键检查点和/或途径的免疫疗法和靶向疗法。本文综述了新型靶向乳腺癌治疗方法，并探讨了联合治疗的可能意义。
In the United States, breast cancer is among the most frequently diagnosed cancers in women. Breast cancer is classified into four major subtypes: human epidermal growth factor receptor 2 (HER2), Luminal-A, Luminal-B, and Basal-like or triple-negative, based on histopathological criteria including the expression of hormone receptors (estrogen receptor and/or progesterone receptor) and/or HER2. Primary breast cancer treatments can include surgery, radiation therapy, systemic chemotherapy, endocrine therapy, and/or targeted therapy. Endocrine therapy has been shown to be effective in hormone receptor-positive breast cancers and is a common choice for adjuvant therapy. However, due to the aggressive nature of triple-negative breast cancer, targeted therapy is becoming a noteworthy area of research in the search for non-endocrine-targets in breast cancer. In addition to HER2-targeted therapy, other emerging therapies include immunotherapy and targeted therapy against critical checkpoints and/or pathways in cell growth. This review summarizes novel targeted breast cancer treatments and explores the possible implications of combination therapy.
登录
查看更多内容
DOI：
10.1016/j.annonc.2020.10.596
发表时间：
2021-03
期刊：
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子：
--
作者：
Dent S;Cortés J;Im YH;Diéras V;Harbeck N;Krop IE;Wilson TR;Cui N;Schimmoller F;Hsu JY;He J;De Laurentiis M;Sousa S;Drullinsky P;Jacot W
通讯作者：
Jacot W
影响因子：
45.3
作者：
Chan, S;Scheulen, ME;Moore, L
通讯作者：
Moore, L
影响因子：
--
作者：
Behravan, Javad;Razazan, Atefeh;Behravan, Ghazal
通讯作者：
Behravan, Ghazal
影响因子：
3.4
作者：
Goulooze, Sebastiaan C.;Cohen, Adam F.;Rissmann, Robert
通讯作者：
Rissmann, Robert
DOI：
10.2147/dddt.s137783
发表时间：
2018
期刊：
Drug design, development and therapy
影响因子：
--
作者：
Corona SP;Generali D
通讯作者：
Generali D